Compare Twilio Inc (TWLO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twilio Inc vs 10X Genomics Inc — how do they compare? Twilio Inc trades at $282.54 (market cap $42.35B), while 10X Genomics Inc trades at $84.15 (market cap $10.07B). The key difference: Twilio Inc is far larger — about 4.2× 10X Genomics Inc's market cap, and 10X Genomics Inc is more actively traded (5,657,286 versus 1,862,642). Which is the better fit depends on your goals — on Pluang, investors hold Twilio Inc for 56 Days and 10X Genomics Inc for 92 Days on average.
| TWLO | TXG | |
|---|---|---|
Market Cap | $42.35B | $10.07B |
Volume | 1,862,642 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $301.27 | $97.74 |
52-Week Low | $106.23 | $11.48 |
Typical Hold Time | 56 Days | 92 Days |
Enterprise Value | $40.76B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twilio (TWLO) trades at $273.00, down 2.64% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $5.07 billion in 2025, turning profitable with a net income of $33.83 million, and has beaten EPS estimates for three consecutive quarters. Recent inclusion in the S&P 500 index and positive analyst sentiment highlight its market position.
Outlook remains positive driven by accelerating revenue growth and Voice AI expansion, but risks include high valuation multiples and competitive pressures. Analyst consensus is bullish with a $254.65 price target, though recent insider selling and a high P/E of 38.09 warrant caution for value-focused investors.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
